本次收购将实现双方优势互补。一方面，威高血净可借助威高普瑞在医药包材领域的技术积累与产品布 局，将产品线从血液净化制品拓展至医药包材赛道，实现多元化经营，降低单一业务领域的政策与市场 风险。另一方面，威高普瑞积累的丰富生物制药客户资源，可为威高血净生物制药滤器业务提供现成的 销售渠道，实现技术储备与市场渠道的双向赋能，共同开拓生物制药上游市场。 从行业背景来看，此次收购契合产业发展趋势。当前国内生物制药产业快速增长，弗若斯特沙利文数据 显示，2024年中国生物药市场规模达5348亿元，预计2032年将增至1.13万亿元，对应的医药包材及生物 制药上游耗材需求同步扩张。与此同时，生物制药上游供应链国产化进程加速，政策支持与市场需求双 重驱动下，具备技术优势的本土企业迎来发展机遇。威高血净通过此次收购，有望快速切入高增长赛 道，提升综合竞争力。 作为本次交易的标的，威高普瑞的经营状况与行业地位受到关注。公开信息显示，威高普瑞成立于2018 年，专注于预灌封给药系统及自动安全给药系统等医药包材业务，致力于为全球生物制药企业提供一站 式药品递送解决方案。财务数据显示，截至2025年6月30日，威高普瑞资产总计34.2 ...

威高血净表示，此次收购核心在于实现业务多元化拓展与技术渠道协同。 本次收购将实现双方优势互补。一方面，威高血净可借助威高普瑞在医药包材领域的技术积累与产品布 局，将产品线从血液净化制品拓展至医药包材赛道，实现多元化经营，降低单一业务领域的政策与市场 风险。另一方面，威高普瑞积累的丰富生物制药客户资源，可为威高血净生物制药滤器业务提供现成的 销售渠道，实现技术储备与市场渠道的双向赋能，共同开拓生物制药上游市场。 从行业背景来看，此次收购契合产业发展趋势。当前国内生物制药产业快速增长，弗若斯特沙利文数据 显示，2024年中国生物药市场规模达5348亿元，预计2032年将增至1.13万亿元，对应的医药包材及生物 制药上游耗材需求同步扩张。与此同时，生物制药上游供应链国产化进程加速，政策支持与市场需求双 重驱动下，具备技术优势的本土企业迎来发展机遇。威高血净通过此次收购，有望快速切入高增长赛 道，提升综合竞争力。 1月5日晚，威高血净（603014）发布公告，拟以发行股份的方式收购山东威高普瑞医药包装有限公司 （简称"威高普瑞"）100%股权，此次交易标的资产评估值为85.11亿元，交易构成重大资产重组。交易 完成后 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603014 证券简称：威高血净 上市地：上海证券交易所 山东威高血液净化制品股份有限公司 发行股份购买资产暨关联交易报告书（草案）摘要 ■ 独立财务顾问 一、上市公司声明 本重大资产重组报告书摘要的目的仅为向公众提供有关本次重组的简要情况，并不包括重大资产重组报 告书全文的各部分内容。重大资产重组报告书全文同时刊载于上海证券交易所网站 （www.sse.com.cn）。 ■ 签署日期：二零二六年一月 声 明 本部分所述词语或简称与本报告书摘要"释义"所述词语或简称具有相同含义。 本公司及本公司全体董事、高级管理人员承诺本报告书摘要及相关信息真实、准确、完整，不存在虚假 记载、误导性陈述或者重大遗漏，并对所提供信息的真实性、准确性、完整性承担相应的法律责任。 如本次交易所披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被 中国证监会立案调查的，在形成调查结论以前，不转让在上市公司拥有权益的股份，并于收到立案稽查 通知的两个交易日内将暂停转让的书面申请和股票账户提交上市公司董事会，由上市公司董事会代为向 证券交易所和证券登记 ...

Core Viewpoint - Weigao Purui, established in 2018, has captured over 50% of the domestic pre-filled syringe market and ranks among the top five internationally, indicating a strong market position and growth potential [1] Financial Performance - Weigao Purui's revenue for 2023 is approximately 1.426 billion, projected to reach 1.684 billion in 2024, and 939 million in the first half of 2025, with net profits of 490 million, 585 million, and 327 million respectively, maintaining a stable net profit margin around 34% [1] - In comparison, Weigao Xuejing's net profits are 442 million, 449 million, and 220 million, with a net profit margin of about 12%, highlighting the superior profitability of Weigao Purui [3] Business Integration - The merger will add pharmaceutical packaging research, production, and sales to the listed company's main business, leveraging technical and customer resource synergies to enhance market presence in the biopharmaceutical sector [8] - The integration is characterized as an internal asset consolidation, aimed at enriching the product structure and unifying resources through the listed platform [9] Market Position and Strategy - Weigao Purui operates in the upstream pharmaceutical packaging sector, primarily serving biopharmaceutical companies, which ensures stable orders and significant technical barriers [11] - The merger combines Weigao Xuejing's extensive sales network and technical expertise in blood purification with Weigao Purui's high-margin pharmaceutical packaging products, creating potential for mutual benefits, especially in the biopharmaceutical filter market [11] Future Outlook - The merger reflects a strategic bet on future growth trajectories, with the success dependent on execution and market response [12]

Group 1: Core Views - Multiple A-shares are set to resume trading, including Dongtu Technology and Weigao Blood Purification, following significant asset restructuring announcements [1][5] - Dongtu Technology plans to acquire 100% of Gaoweike, with the transaction expected to meet the criteria for a major asset restructuring [2][4] - Weigao Blood Purification intends to purchase 100% of Weigao Puri, also anticipated to constitute a major asset restructuring [5][6] Group 2: Dongtu Technology - Dongtu Technology will issue shares and pay cash to acquire Gaoweike, which will become a wholly-owned subsidiary post-transaction [2] - The share issuance price is set at 18.56 yuan per share, representing 80% of the average trading price over the previous 120 trading days [2] - The acquisition aims to enhance Dongtu's capabilities in providing comprehensive solutions and improve its market competitiveness [4] Group 3: Gaoweike Overview - Gaoweike, established in 2001, specializes in industrial automation and control systems, serving various manufacturing sectors [3] - The company has developed core products in motion control, including PLCs and servo systems, and has a broad customer base across China [3] Group 4: Weigao Blood Purification - Weigao Blood Purification's acquisition of Weigao Puri will expand its product line into pre-filled drug delivery systems and automatic safety delivery systems [7] - The company reported a total revenue of 2.736 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 3.45% [7]

Core Viewpoint - Multiple A-shares are set to resume trading, with significant asset restructuring announcements from Dongtu Technology and Weigao Blood Purification [1][6] Group 1: Dongtu Technology - Dongtu Technology plans to acquire 100% of Gaoweike through a combination of issuing shares and cash payments, with the stock resuming trading on November 3 [2] - The acquisition is expected to meet the criteria for a major asset restructuring, with the share price set at 18.56 yuan per share, which is 80% of the average trading price over the last 120 trading days [2] - Gaoweike, established in 2001, specializes in industrial automation and control systems, serving various sectors including new energy batteries and consumer electronics [3] - The acquisition aims to enhance Dongtu Technology's capabilities in providing comprehensive solutions and improve its competitiveness in the market [4] - In the first three quarters of 2025, Dongtu Technology reported a revenue of 500 million yuan, a year-on-year decrease of 11.72%, primarily due to a strategic shift in business structure [4] - New business segments, including smart controllers and industrial operating systems, showed significant growth, with order amounts increasing by 87.55% and 13.63% respectively [4] - Dongtu Technology is also strategically investing in the embodied robotics sector, indicating a broader focus on technological advancements [5] Group 2: Weigao Blood Purification - Weigao Blood Purification intends to acquire 100% of Weigao Puri through a share issuance, with the stock also resuming trading on November 3 [6] - The acquisition is anticipated to constitute a major asset restructuring, with the valuation and transaction price yet to be determined [6] - Weigao Puri, founded in 2005, is a leading manufacturer of pre-filled syringes, holding over 50% market share in China and ranking among the top five globally [6][7] - Post-acquisition, Weigao Blood Purification will diversify its business to include the development and production of medical packaging products, enhancing its resilience and growth potential [7] - For the first three quarters of this year, Weigao Blood Purification reported total revenue of 2.736 billion yuan, a year-on-year increase of 3.45%, with a net profit of 341 million yuan, up 7.92% [7]

Group 1 - The core point of the news is that Shandong Weigao Blood Purification Products Co., Ltd. is undergoing a significant asset restructuring by acquiring 100% equity of Weigao Puri, which will enhance its product line and operational capabilities in the pharmaceutical packaging sector [1][2] - The transaction is expected to strengthen the integration of the supply chain, improve control over key raw materials and packaging processes, and enhance the overall asset quality and profitability of Weigao Blood Purification [2][3] - Weigao Blood Purification has shown steady performance since its listing, with a reported revenue of 2.736 billion yuan and a net profit of 341 million yuan for the first three quarters of the year, reflecting year-on-year growth of 3.45% and 7.92% respectively [3] Group 2 - The acquisition is seen as a strategic move to tap into the growing demand for pharmaceutical packaging materials and upstream products in the biopharmaceutical sector, driven by the rapid development of the biopharmaceutical industry [2][3] - The blood purification industry is projected to have significant growth potential due to increasing patient numbers requiring blood purification treatments, particularly in the context of an aging population [3] - The transaction is still subject to further approvals, including board and shareholder meetings, as well as regulatory approvals from the Shanghai Stock Exchange and the China Securities Regulatory Commission [3]